Avanti NanoSciences is Developing Smart Technologies for Rapid, Reagent-Free Detection for Pathogenic E. coli O157:H7

Baltimore, MD (PRWEB) September 25, 2006

Avanti NanoSciences, a company developing smart technologies for rapid, portable detection systems for harmful pathogens, today announced that it has developed a rapid and ultra sensitive detection test for pathogenic E. coli O157:H7.

A rapid test for detection and monitoring of pathogenic E.coli is pertinent considering the recent outbreaks of this food pathogen in leafy greens. “E. coli cases linked to tainted spinach have been reported in 21 states: California, Connecticut, Idaho, Illinois, Indiana, Kentucky, Maine, Michigan, Minnesota, Nebraska, New Mexico, Nevada, New York, Ohio, Oregon, Pennsylvania, Utah, Virginia, Washington, Wisconsin and Wyoming, according to the Centers for Disease Control and Prevention. Wisconsin has reported the most cases, including the death of a 77-year-old woman. A death in Ohio was being investigated. (CNN, Associated Press-Sept. 19, 2006)”

Avanti’s E. coli O157:H7 test is part of its Pathfinder™ system, which is based on the NanoBindi technology. The system utilizes target-induced fluorescence from affinity molecule-functionalized nanoparticles. The assay methodology incorporates Avanti Nanosciences’ smart technology protocol that incorporates no or minimal sample preparation, no reagents, no target amplification and simple-to-use instrumentation to facilitate extremely rapid testing of pathogens at previously unachievable levels of speed and sensitivity.

The technology is expected to play a significant role in the rapid detection of infectious agents.

“We believe that the evaluation testing will increase operational efficiencies for these market leading testing labs and will simultaneously validate that Avanti NanoScience’s E. coli O157:H7 test offers an unprecedented combination of speed and sensitivity,” said Arkesh Mehta, Founder and CEO of Avanti NanoSciences.

About Avanti NanoSciences,

Avanti NanoSciences is a privately held company developing novel technologies for the rapid detection of pathogens. The Company's technology is expected to have broad applications in food testing, animal health, and human health care, including drug discovery and development and disease diagnosis. Avanti NanoSciences is developing PathFinderTM technology platform, a family of next generation, early warning detection devices providing a real-time method for pathogen detection, identification and monitoring.

Avanti NanoScience’s patent-pending NanoBindi technology is the basis for an open and ultra sensitive solution which can detect the presence of pathogens including food pathogens, and other weaponized bio-agents. The elegance of the technology provides for a marked improvement in price/performance over current solutions and a drastic reduction in entry price which creates new market opportunities for providing first level protection for food security, water systems, consumer products and Homeland Security. Avanti Nanosciences’s initial focus is to provide smart detection capabilities for detection and monitoring of consumer food supply.

Additional information is available at http://www.analytics.at-gc.com
This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Avanti NanoSciences mission to develop and commercialize instrument systems, Avanti NanoSciences’ ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

Avanti NanoSciences cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Avanti NanoSciences’ expectations that they will incur operating losses in the near future, the early stage of development of Avanti NanoSciences’ products and technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Avanti NanoSciences’ reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Avanti NanoSciences products, processes and technologies, Avanti NanoSciences’ ability to protect their patents and proprietary rights and uncertainties relating to commercialization.

For further details related to our capabilities please contact:

Media Relations

Avanti NanoSciences

7720, Bel Air Road, Suite 250

Baltimore, MD 21236

http://www.analytics.at-gc.com
(301) 540-5474 (Tel.)

(270) 447- 4777(FAX)

###